The Chinese drug market for diabetes is dominated by traditional drugs. In 2018, the sales of GLP-1 drugs under this project were only RMB 700 million yuan, accounting for only 1.2%. The number during the same period in the United States was USD 5.6 billion, accounting for 15.5%. This suggests that there is huge growth room for GLP-1 drugs.